ADC In Vitro Evaluation
Optimizing precision in oncologic treatments
The success of antibody-drug conjugates (ADCs) hinges on intricate interplay between antibody targeting, drug release, and cellular response. For researchers navigating this complex landscape, comprehensive in vitro evaluation is crucial to optimize your ADC’s potential. Our meticulously designed suite of assays delves into every aspect of your ADC, providing unparalleled insights to guide your development journey.
MODELS / SERVICES
Committed to quality:
- FDA part 11 compliant
- Animal studies strictly follow AAALAC and ILAC guidelines
- Electronically managed, traceable research data
- Rigorous adherence to international GLP and QA best practices
- Clients have real-time remote monitoring of studies
Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.
Providing Better Data For Critical Oncology Pipeline Decisions
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.
Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.
We’re ready when you are.
Tell us your pharmacology challenges.
